Sage Journals: Discover world-class research

Retricted access

Article commentary

First published 2019-1

Inferior outcomes in immunocompromised Merkel cell carcinoma patients: Can they be overcome by the use of PD1/PDL1 inhibitors?

Constantin A Dasanu, Michael Del Rosario, Ion Codreanu [...]

Journal of Oncology Pharmacy Practice

Retricted access

Review article

First published 2025-5

Bispecific antibodies (bsAbs) directed against PD-1/PD-L1 and CTLA-4;a mini review

Amirhossein Mardi, Leili Aghebati-Maleki

Human Antibodies

Free access

Research article

First published 2024-5

PDL1 immunohistochemistry in canine neoplasms: Validation of commercial antibodies,standardization of evaluation,and scoring systems

Luisa Vera Muscatello, Francesca Gobbo, Giancarlo Avallone [...]

Veterinary Pathology

Free access

Review article

First published 2021-12

Higher Tumor Mutation Burden Was a Predictor for Better Outcome for NSCLC Patients Treated with PD-1 Antibodies: A Systematic Review and Meta-analysis

Yuhui Zheng, Meihong Yao, Yinghong Yang

Journal of Laboratory Automation

Open access

Review article

First published 2025

The Role of Immunotherapy in Salivary Gland Cancer: A Systematic Review

Sul Gi Kim, Jason Tasoulas, Siddharth Sheth [...]

Ear,Nose & Throat Journal

Open access

Review article

First published 2019

Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management

Uday N. Shivaji, Louisa Jeffery, Xianyong Gui [...]

Therapeutic Advances in Gastroenterology

Open access

Review article

First published 2020-07-02

First-Line Immune Checkpoint Inhibitor-Based Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review

Myuran Thana, Lori Anne Wood

Kidney Cancer

Open access

Research article

First published 2025

A Prognostic Risk Signature Based on Myeloid-Derived Suppressor Cells and Regulatory T Cells in Clear Cell Renal Cell Carcinoma

Zhaoyu Xu, Ken Liu, Qiangqiang Xu [...]

Technology in Cancer Research & Treatment

Open access

Research article

First published 2020-10

Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition

Qiong Lyu, Anqi Lin, Manming Cao [...]

Cancer Control

Search results